Last reviewed · How we verify
Transdermal Lidocaine Patch
Lidocaine blocks sodium channels in nerve fibers, interrupting pain signal transmission when applied topically through a transdermal patch.
Lidocaine blocks sodium channels in nerve fibers, interrupting pain signal transmission when applied topically through a transdermal patch. Used for Postherpetic neuralgia (localized neuropathic pain), Localized pain relief.
At a glance
| Generic name | Transdermal Lidocaine Patch |
|---|---|
| Also known as | Actavis US, NDC 0591-3525-30, 5% Commercially Available Transdermal Lidocaine |
| Sponsor | University of Wisconsin, Madison |
| Drug class | Local anesthetic |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Pain management |
| Phase | FDA-approved |
Mechanism of action
Lidocaine is a local anesthetic that penetrates the skin and underlying tissues to reversibly inhibit sodium influx in nerve cell membranes, thereby preventing depolarization and conduction of pain impulses. The transdermal patch formulation provides sustained, localized delivery to affected areas, minimizing systemic absorption and side effects compared to oral or injectable routes.
Approved indications
- Postherpetic neuralgia (localized neuropathic pain)
- Localized pain relief
Common side effects
- Skin irritation or erythema at application site
- Allergic contact dermatitis
- Mild systemic effects (dizziness, headache) from transdermal absorption
Key clinical trials
- To Check Dermatological Safety of Test Products by 24 Hours Patch Testing (NA)
- The OBstetric Lidocaine Patch (OBLido) Trial (PHASE4)
- Transdermal Microneedle Lignocaine Delivery Versus EMLA Patch for Topical Analgesia Before Venepuncture Procedure To Adults in Clinical Setting (PHASE1, PHASE2)
- Lidocaine Patches in Elderly Patients With Traumatic Rib Fractures (PHASE4)
- Effectiveness of Nitrous Oxide 50% for Reducing Pain and Distress Associated with Needle-stick in Children (NA)
- Safety and Efficacy of SP-103 in Subjects With Moderate to Severe Acute Lower Back Pain (PHASE2)
- Pharmacokinetic Study of Lidocaine Patch 1.8% Lidocaine Patch 5% (Lidoderm®) in Healthy Subjects (PHASE1)
- Adjunctive 5% Lidocaine Patches for Acute Non-radicular Low Back Pain in Emergency Department Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |